Regeneron Pharmaceuticals, Inc.

Aventis Pharma S.a.

University of California

Columbia University

Jocelyn Holash

Jesse M Cedarbaum

George D Yancopoulos

John Rudge

Neil E Stahl

Eric Steven Furfine

Marie-Christine Bissery

Candelaria Gomez-Manzano

W K Alfred Yung

Patricia Vrignaud

Marielle Chiron-Blondel

Juan Fueyo

Jessica Kandel

Darrell Yamashiro

Jianzhong Huang

Robert Jaffe

Limin Hu

This invention relates to antitumor combinations comprising a VEGF inhibitor combined with 5-fluorouracil or with a 5-fluoropyrimidine derivative that are therapeutically useful in the treatment of neoplastic diseases, and pharmaceutical compositions comprising such combinations.

Antitumor combinations containing a VEGF-inhibiting agent and 5FU or a derivative thereof

Disclosed are compositions and methods for treating a disease or condition related to angiogenesis with a vascular endothelial growth factor (VEGF) inhibitor and one or more anti-hypertensive agent(s). The method of the invention is useful for preventing the development of hypertension and/or reducing hypertension in a subject treated with a VEGF inhibitor.

Therapeutic combination of a VEGF antagonist and anti-hypertensive agent

Methods of treating cancer and/or reducing or inhibiting tumor growth in a subject in need thereof, comprising administering pharmaceutical composition comprising a vascular endothelial cell growth factor (VEGF) antagonist, such as a VEGF trap, an anti-proliferative agent, such as taxol, and a pharmaceutically acceptable carrier.

Method of treating cancer with a VEGF antagonist and an anti-proliferative agent

Methods of regressing or inhibiting a tumor in a subject by administering an agent capable of blocking, inhibiting, or ameliorating vascular endothelial growth factor (VEGF)-mediated activity to a subject in need thereof such that the tumor is regressed or inhibited. The method of the invention results in a reduction of tumor size and inhibition of tumor metastases. This method is particularly useful for patients suffering from bulky, metastatic cancers.

Method of tumor regression with VEGF inhibitors

Methods for treating a human patient suffering from a brain tumor, including glioblastoma, by administering an effective amount of a vascular endothelial growth factor (VEGF) inhibitor to the human patient. The VEGF inhibitor is a VEGF antagonist protein comprising a dimeric protein having two fusion polypeptides having the sequence of SEQ ID NO:2.

Use of VEGF antagonists for the treatment of malignant gliomas

Methods of treating anemic disorders in human subjects comprising administering a VEGF antagonist comprising a fusion polypeptide having an immunoglobulin-like (Ig) domain 2 of the VEGF receptor Flt1 and Ig domain 3 of the VEGF receptor Flk1 or Flt4, and a multimerizing component. Further included are methods of preventing anemia, increasing hematocrit levels, and increasing or stimulating erythropoietin, particularly in subjects being treated for cancer with chemotherapeutic agents and/or radiation.

Methods of treating anemia by inhibition of vascular endothelial growth factor (VEGF)

Growing community of inventors

Alameda, CA, United States of America

Jocelyn Holash